2011年16家增长最快的明星公司

Celgene生物制药公司

排名：第57位

连续在榜年数：3年

    这家生物制药公司去年进行了两笔重大并购——买下了制药公司Gloucester和生物技术公司Abraxis——以推进其成为肿瘤治疗领域领导者的目标。在国际扩张、销售增长和近期并购等因素助力下，该公司今年销售收入增长9.359亿美元，达到36亿美元。

    2009年，药物萨力多胺（Thalidomide，一种安眠药，镇静剂——译注）大获成功，Celgene公司首度登上本榜单，排在第22位。该药此前曾因会引起先天畸型而遭禁，但此后即改变用途，成为多发性骨髓瘤的特效药。现在，公司可以靠雷利米得（Revlimid）和阿扎胞苷（Vidaza，治疗血液和骨髓疾病）来获得销售收入的持续增长。

Celgene

100 Fastest-Growing Rank: 57

Consecutive years on the list: 3

    The biopharmaceutical company made two major acquisitions last year -- the pharmaceutical company Gloucester and biotech firm Abraxis -- to advance its goal of becoming an oncology leader. Revenues this year grew by $935.9 million to hit $3.6 billion, aided by the company's international expansion, sales growth, and its newly acquired companies.

    Celgene made its debut on Fortune's Fastest-Growing Companies list in 2009 at No. 22, riding on the success of its drug Thalidomide, which was previously shunned for causing birth defects but was repurposed as a treatment for multiple myeloma. It now can credit drugs Revlimid and Vidaza (for blood and bone marrow conditions) for its continued growth in revenues.